$18.45 billion! Sanofi (SNY.US) heavily invests in the field of autoimmune and inflammatory bowel diseases.

On April 17th, Earendil Labs announced a licensing agreement with Sanofi (SNY.US) for two potential first-in-class bispecific antibodies in the field of autoimmune and inflammatory bowel diseases. According to the agreement, Sanofi will receive global exclusive rights to the two bispecific antibodies, HXN-1002 and HXN-1003, both of which will be developed using Earendil Labs' proprietary artificial intelligence and high-throughput discovery and research platform. As part of the agreement, Earendil Labs will receive an upfront payment of $125 million and be eligible for total development and commercial milestone payments of up to $1.72 billion, including a $50 million upfront payment. In addition, Earendil Labs stands to receive tiered royalties on product sales ranging from high single digits to low double digits.